[EN] - Why cutting-edge AI research doesn't scale by itself ?

Cutting-edge research does not necessarily guarantee patient access.

Welcome to Pharma Minds, Mini-Series “Who controls innovation?". In this mini-series, we explore one question in two parts: who controls innovation and who actually makes it happen.

Artificial intelligence in oncology is booming. Public programs, private partnerships, and massive volumes of data are driving the field forward. Yet, as China closely observes European research, a critical issue remains: the gap between academic excellence and actual industrial deployment.

In this episode, we explore where strategy meets reality with Prof. Nathalie Lassau, radiologist at the Gustave Roussy Institute (IGR), professor at Paris Saclay University, and INSERM researcher.

Prof. Lassau is a master of execution. From labeling 55,000 metastases to integrating her innovations into ultrasound machines worldwide, she has spent her career bridging the gap between research, clinical practice, and private industry.

Driven by relentless pragmatism and resilience, she collaborates with giants like INRIA, Canon Medical, OWKIN, and Guerbet to build revolutionary platforms for cancer prevention and treatment.

But despite these massive efforts, the patient often remains caught in a fragile position between lab breakthroughs and bedside access.

In this episode, we cover:

◾️ The reality of AI in Oncology: How massive data and public-private partnerships are transforming cancer care.

◾️ The execution gap: Why Europe produces world-class research but struggles with equal patient access.

◾️ Building bridges: Prof. Lassau’s insights on forcing collaboration between academia and the private sector.

◾️ The global observation: How China is watching Europe's AI advancements.

◾️ The power of resilience: How overcoming structural obstacles is required to drive true medical innovation.

If Europe excels in AI research, why does access remain unequal? Is it regulation, industrial caution, or the fragmentation of our healthcare systems?

👉 In your country, what is the biggest barrier to accessing AI? Is it funding, regulation, or collaboration between industry and academia? Let us know in the comments.

Next time, we address another structural gap: why are there 100 new drugs already available in the US, but not in Europe?

Science creates hope. Reality decides impact. If you want to follow the whole series, don't forget to subscribe!

-

This episode has been translated with the help of AI tools. 

Originally released on: April 22th 2024. 

To listen to the original French version of this episode : https://smartlink.ausha.co/pharma-minds/pr-nathalie-lassau-puph-radiologue-paris-saclay-innover-c-est-decloisonner-et-rester-pragmatique

Hébergé par Ausha. Visitez ausha.co/politique-de-confidentialite pour plus d'informations.